Abeona Therapeutics Inc.
ABEO
$4.95
$0.275.77%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | 227.72% | 147.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | 227.72% | 147.52% |
| Cost of Revenue | 1.65% | 130.85% | 75.83% | 47.59% | 37.86% |
| Gross Profit | -11.25% | -194.18% | -110.44% | -40.14% | -32.32% |
| SG&A Expenses | 57.08% | 48.51% | 38.54% | 29.95% | 10.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.20% | 20.19% | 16.76% | 22.88% | 10.78% |
| Operating Income | -33.22% | -29.31% | -26.02% | -17.77% | -6.50% |
| Income Before Tax | -17.62% | -58.84% | -33.79% | -186.48% | -36.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.62% | -58.84% | -33.79% | -186.48% | -36.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.62% | -58.84% | -33.79% | -186.48% | -36.51% |
| EBIT | -33.22% | -29.31% | -26.02% | -17.77% | -6.50% |
| EBITDA | -35.49% | -32.26% | -29.62% | -21.15% | -8.89% |
| EPS Basic | 30.73% | 9.11% | 30.11% | 6.57% | 61.37% |
| Normalized Basic EPS | 32.23% | 8.36% | 29.65% | -10.63% | 48.66% |
| EPS Diluted | 13.42% | -9.01% | 15.16% | 6.57% | 61.37% |
| Normalized Diluted EPS | 30.70% | 6.70% | 28.29% | -10.63% | 48.66% |
| Average Basic Shares Outstanding | 92.11% | 92.93% | 115.15% | 125.22% | 171.68% |
| Average Diluted Shares Outstanding | 105.24% | 108.27% | 135.64% | 125.22% | 171.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
